Last update 17 Aug 2026

SPX-306

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
SPX-306
Target
IL-23 x TL1A
Action
inhibitors
Mechanism
IL-23 inhibitors(Interleukin-23 inhibitors), TL1A inhibitors(Tumor necrosis factor superfamily member 15 inhibitors)
Therapeutic Areas
Neoplasms
Active Indication
Neoplasms
Inactive Indication-
Originator Organization
SparX Therapeutics, Inc.SparX Therapeutics, Inc.
Active Organization
SparX Therapeutics, Inc.SparX Therapeutics, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePreclinical
First Approval Date-
Regulation-

Related

100 Clinical Results associated with SPX-306
Login to view more data
100 Translational Medicine associated with SPX-306
Login to view more data
100 Patents (Medical) associated with SPX-306
Login to view more data
100 Deals associated with SPX-306
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPreclinical
United States
SparX Therapeutics, Inc.SparX Therapeutics, Inc.
15 Feb 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free